Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Yves Beguin, University Hospital of Liege
ClinicalTrials.gov Identifier:
NCT00504803
First received: July 19, 2007
Last updated: September 1, 2011
Last verified: September 2011

July 19, 2007
September 1, 2011
December 2006
December 2010   (final data collection date for primary outcome measure)
Day-100 incidence of non-relapse mortality [ Time Frame: 100 days ] [ Designated as safety issue: Yes ]
Day-100 incidence of non-relapse mortality [ Time Frame: 100 days ]
Complete list of historical versions of study NCT00504803 on ClinicalTrials.gov Archive Site
1. Hematopoietic engraftment and graft rejection. 2. Incidence of grade II-IV and III-IV acute GVHD. 3. Immunologic reconstitution [ Time Frame: 365 days ] [ Designated as safety issue: Yes ]
1. Hematopoietic engraftment and graft rejection. 2. Incidence of grade II-IV and III-IV acute GVHD. 3. Quality and timing of immunologic recon [ Time Frame: 365 days ]
Not Provided
Not Provided
 
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning: a Pilot Study

Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning from HLA-mismatched PBSC or cord blood: a Pilot Study

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Hematological Malignancies
Procedure: Mesenchymal stem cell infusion
Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.
Other Name: Mesenchymal stem cells
Experimental: 1
MSC co-infusion with either HLA-mismatched PBSC or cord blood
Intervention: Procedure: Mesenchymal stem cell infusion
Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L, Vanbellinghen JF, Hafraoui K, Lejeune M, Gothot A, Fillet G, Beguin Y. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant. 2010 Jun;16(6):838-47. Epub 2010 Jan 28.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
December 2010
December 2010   (final data collection date for primary outcome measure)

V.1. Patients

V.1.1. Diseases

Hematological malignancies confirmed histologically and not rapidly progressing:

  • AML in CR;
  • ALL in CR;
  • CML unresponsive/intolerant to Imatinib but not in blast crisis;
  • Other myeloproliferative disorders not in blast crisis and not with extensive myelofibrosis;
  • MDS with < 5% blasts;
  • Multiple myeloma;
  • CLL;
  • Non-Hodgkin's lymphoma (aggressive NHL should have chemosensitive disease);
  • Hodgkin's disease.

V.1.2. Clinical situations

  • Theoretical indication for a standard allo-transplant, but not feasible because:

    • Age > 55 yrs;
    • Unacceptable end organ performance;
    • Patient's refusal.
  • Indication for a standard auto-transplant: perform mini-allotransplantation 2-6 months after standard autotransplant.

V.1.3. Other inclusion criteria

  • Male or female; fertile female patients must use a reliable contraception method;
  • Age < 75 yrs.
  • Informed consent given by patient or his/her guardian if of minor age.

V.1.4. Exclusion criteria

  • Any condition not fulfilling inclusion criteria;
  • HIV positive;
  • Terminal organ failure, except for renal failure (dialysis acceptable);
  • Uncontrolled infection, arrhythmia or hypertension;
  • Previous radiation therapy precluding the use of 2 Gy TBI;
  • HLA-identical donor.

V.2. PBSC donors

V.2.1. Inclusion criteria

  • Related to the recipient (sibling, parent or child) or unrelated;
  • Male or female;
  • Weight > 15 Kg (because of leukapheresis);
  • Fulfills generally accepted criteria for allogeneic PBSC donation;
  • Informed consent given by donor or his/her guardian if of minor age, as per donor center standard procedures.

V.2.2. Exclusion criteria

  • Any condition not fulfilling inclusion criteria;
  • HIV positive;
  • Unable to undergo leukapheresis because of poor vein access or other reasons.

V.2.3. HLA matching

Related or unrelated donors who have 1-2 HLA mismatches, as either :

  • One antigenic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1
  • One allelic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1
  • Two allelic mismatches at HLA-A or -B or -C or -DRB1 or -DQB1
  • One antigenic mismatch + 1 allelic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1.
  • One antigenic mismatch at -DQB1 and one other antigenic mismatch at HLA-A or -B or -C or -DRB1

V.3. Cord blood unit

Banked cord blood units will be used if they fulfill the following criteria:

  • No more than 2/6 HLA mismatches (antigenic mismatch at HLA-A or HLA-B or allelic mismatch at HLA-DRB1)
  • > 2.5 x 107 TNC/kg
  • Standard validation by FACT/Netcord criteria.
Both
up to 75 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Belgium
 
NCT00504803
TJB0601
No
Yves Beguin, University Hospital of Liege
University Hospital of Liege
Not Provided
Principal Investigator: Frederic Baron, MD, PhD CHU-ULg
Principal Investigator: Yves Beguin, MD, PhD CHU-ULg
Study Chair: Chantal Lechanteur, PhD CHU-ULg
Study Chair: Etienne Baudoux, MD CHU-ULg
Study Chair: Evelyne Willems, MD CHU-ULg
University Hospital of Liege
September 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP